Related Experiment Video
Updated: Apr 22, 2026
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside
V Boisguérin1, J C Castle2, M Loewer2
11] TRON gGmbH-Translational Oncology at Johannes Gutenberg-University Medical Center gGmbH, Langenbeckstr 1, Building 708, 55131 Mainz, Germany [2] BioNTech AG, Hölderlinstr 8, 55131 Mainz, Germany.
Abstract:
Cancer is a disease caused by DNA mutations. Cancer therapies targeting defined functional mutations have shown clinical benefit. However, as 95% of the mutations in a tumour are unique to that single patient and only a small number of mutations are shared between patients, the addressed medical need is modest. A rapidly determined patient-specific tumour mutation pattern combined with a flexible mutation-targeting drug platform could generate a mutation-targeting individualised therapy, which would benefit each single patient. Next-generation sequencing enables the rapid identification of somatic mutations in individual tumours (the mutanome). Immunoinformatics enables predictions of mutation immunogenicity. Mutation-targeting RNA-based vaccines can be rapidly and affordably synthesised as custom GMP drug products. Integration of these cutting-edge technologies into a clinically applicable process holds the promise of a disruptive innovation benefiting cancer patients. Here, we describe our translation of the individualised RNA-based cancer vaccine concept into clinic trials.
Insights
This study translates individualized RNA-based cancer vaccines into clinical trials. This approach targets unique tumor mutations for personalized cancer therapy, aiming to improve patient outcomes.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Cancer arises from DNA mutations, with most tumor mutations being patient-specific.
- Current therapies targeting shared mutations offer limited benefit due to tumor heterogeneity.
- Individualized therapies are needed to address the vast majority of unique cancer mutations.
Purpose of the Study:
- To translate the concept of individualized RNA-based cancer vaccines into clinical trials.
- To develop a platform for rapid, affordable, and personalized cancer treatment.
- To leverage cutting-edge technologies for improved cancer patient benefit.
Main Methods:
- Utilizing next-generation sequencing to identify patient-specific tumor mutations (mutanome).
- Employing immunoinformatics to predict the immunogenicity of identified mutations.
- Synthesizing custom GMP-grade, mutation-targeting RNA-based vaccines.
Main Results:
- Successfully translated the individualized RNA-based cancer vaccine concept.
- Demonstrated the feasibility of integrating sequencing, immunoinformatics, and vaccine synthesis.
- Initiated clinical trials to evaluate the efficacy of this personalized approach.
Conclusions:
- Individualized RNA-based cancer vaccines represent a promising, disruptive innovation in oncology.
- This approach has the potential to significantly benefit individual cancer patients by targeting their unique mutanome.
- Integration of advanced technologies offers a pathway to personalized cancer therapy.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:27Tumor Immunotherapy